BR112018007399A2 - composição, método de tratamento, kit de partes e forma de dosagem - Google Patents

composição, método de tratamento, kit de partes e forma de dosagem

Info

Publication number
BR112018007399A2
BR112018007399A2 BR112018007399A BR112018007399A BR112018007399A2 BR 112018007399 A2 BR112018007399 A2 BR 112018007399A2 BR 112018007399 A BR112018007399 A BR 112018007399A BR 112018007399 A BR112018007399 A BR 112018007399A BR 112018007399 A2 BR112018007399 A2 BR 112018007399A2
Authority
BR
Brazil
Prior art keywords
composition
treatment
dosage form
part kit
kit
Prior art date
Application number
BR112018007399A
Other languages
English (en)
Portuguese (pt)
Inventor
Mayo John
Wolf-Garraway Richard
Henry William
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of BR112018007399A2 publication Critical patent/BR112018007399A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018007399A 2015-10-14 2016-10-14 composição, método de tratamento, kit de partes e forma de dosagem BR112018007399A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (1)

Publication Number Publication Date
BR112018007399A2 true BR112018007399A2 (pt) 2018-10-16

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007399A BR112018007399A2 (pt) 2015-10-14 2016-10-14 composição, método de tratamento, kit de partes e forma de dosagem

Country Status (15)

Country Link
US (3) US20190192664A1 (cg-RX-API-DMAC7.html)
EP (1) EP3362039A1 (cg-RX-API-DMAC7.html)
JP (1) JP7160678B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180067616A (cg-RX-API-DMAC7.html)
CN (1) CN108472246A (cg-RX-API-DMAC7.html)
AU (1) AU2016336929B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018007399A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036111C (cg-RX-API-DMAC7.html)
EA (1) EA201890703A1 (cg-RX-API-DMAC7.html)
GB (1) GB201518172D0 (cg-RX-API-DMAC7.html)
HK (1) HK1256814A1 (cg-RX-API-DMAC7.html)
IL (1) IL258567B2 (cg-RX-API-DMAC7.html)
MX (1) MX391574B (cg-RX-API-DMAC7.html)
SG (2) SG11201802956RA (cg-RX-API-DMAC7.html)
WO (1) WO2017064276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115190883A (zh) * 2019-11-07 2022-10-14 伊利诺伊大学评议会 治疗脓毒症、动脉粥样硬化、血栓形成、中风、心脏病发作和炎症的肽和方法
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE179599T1 (de) 1993-08-06 1999-05-15 Opperbas Holding Bv Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
ES2233036T3 (es) 1998-04-27 2005-06-01 Opperbas Holding B.V. Composicion farmaceutica que comprende factor viii y liposomas neutros.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
RU2250911C2 (ru) 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
US20070141135A1 (en) * 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
ATE395101T1 (de) 2003-04-15 2008-05-15 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
EP2437726B1 (en) 2009-06-03 2018-05-16 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
AU2010283998B2 (en) 2009-08-21 2015-01-29 Targeted Delivery Technologies Limited Vesicular formulations
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB2516388A (en) 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
JP6352950B2 (ja) * 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物

Also Published As

Publication number Publication date
US20250170244A1 (en) 2025-05-29
GB201518172D0 (en) 2015-11-25
CA3036111A1 (en) 2017-04-20
EP3362039A1 (en) 2018-08-22
SG10202010711UA (en) 2020-12-30
EA201890703A1 (ru) 2018-11-30
IL258567B1 (en) 2025-04-01
HK1256814A1 (zh) 2019-10-04
IL258567B2 (en) 2025-08-01
MX391574B (es) 2025-03-21
SG11201802956RA (en) 2018-05-30
US20210093721A1 (en) 2021-04-01
CN108472246A (zh) 2018-08-31
AU2016336929B2 (en) 2022-09-29
US20190192664A1 (en) 2019-06-27
JP2018535952A (ja) 2018-12-06
KR20180067616A (ko) 2018-06-20
IL258567A (en) 2018-05-31
MX2018004445A (es) 2018-08-14
JP7160678B2 (ja) 2022-10-25
AU2016336929A1 (en) 2018-05-10
WO2017064276A1 (en) 2017-04-20
CA3036111C (en) 2023-06-06

Similar Documents

Publication Publication Date Title
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX2022010774A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112018007560A2 (pt) composição cosmética tendo bactérias probióticas
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112018007399A2 (pt) composição, método de tratamento, kit de partes e forma de dosagem
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX380429B (es) Composición para tratar lesiones tisulares.
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
IL251555B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]